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ABSTRACT 
Background: Recent estimates suggesting that over half of Alzheimer's disease (AD) burden 
worldwide might be attributed to potentially modifiable risk factors do not take into account 
risk factor non-independence. This paper provides specific, and more realistic, estimates of 
preventive potential accounting for the correlation between risk factors. 
Methods:  The population attributable risk (PAR) of AD worldwide, USA, Europe and the UK 
relating to seven potentially modifiable risk factors for AD identified as having consistent 
evidence for an association (diabetes, midlife hypertension, midlife obesity, physical 
inactivity, smoking, depression and educational attainment) was estimated using relative 
risks from existing meta-analyses. The combined PAR associated with the risk factors was 
estimated, using data from the Health Survey for England 2006 to estimate and adjust for the 
correlation between risk factors.  
Findings: Worldwide 19.1% of AD cases may be attributable to low educational attainment. In 
the USA, Europe and the UK the largest proportion of cases may be attributable to physical 
inactivity – 21.0%, 20.3%, and 21·8%, respectively.  Assuming independence, the seven risk 
factors’ combined worldwide PAR was 49.4% (i.e. contributing to 16.7 million out of 33.9 
million cases). However, adjusting for the correlation between the risk factors the estimate 
reduced to 28.2% (i.e. contributing to 9.6 million out of 33.9 million cases). Similar combined 
PAR estimates were found for the USA, Europe and the UK.  
Interpretation: Even after accounting for non-independence between modifiable risk factors 
for AD, assuming a causal relationship, around one-third of AD cases in Europe and the UK 
may be attributable to the risk factors considered.  This provides an indication for the 
potential size of reduction of AD through the improvements in education and deploying 
effective methods for population reduction of vascular risk. 
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RESEARCH IN CONTEXT 
Systematic review 
PubMed (1 January 1994 to 30 May 2014) was searched to identify systematic reviews that 
provide population attributable risks (PAR) estimates of Alzheimer's disease for the seven 
modifiable risk factors considered (diabetes, midlife hypertension, midlife obesity, physical 
inactivity, smoking, depression and educational attainment). Separate searches were 
conducted specifying: <risk factor> AND (attributable risk OR attributable fraction) AND 
(Alzheimer's disease OR dementia). One systematic review provided combined PAR 
estimates for all risk factors.1 Four systematic reviews provided individual PAR estimates for 
diabetes,1–3 midlife hypertension,1,3 midlife obesity,1,3,4 physical inactivity,1 smoking,1 
depression,1 and educational attainment.1 
Interpretation 
In line with a previous estimate of the combined proportion of cases attributable to the risk 
factors considered,1 around half of cases AD cases may be attributable to potentially 
modifiable factors. However, more realistically, taking the correlation between these risk 
factors into account, this study estimates around one-third of the AD cases may be 
attributable to potentially modifiable factors. PAR estimates for each risk factor individually 
were broadly similar to most previous estimates,1,2,4 Higher PAR estimates relating to midlife 
obesity and hypertension were reported by one study due to the higher prevalence estimates 
of the risk factors used by that study.3 Several previous studies have considered the effect of a 
hypothetical intervention delaying the onset of AD (i.e. reduced incidence) and thereby 
reducing the future prevalence of AD in the USA US.5,6 This study considers specific risk 
factors and also provides estimates for the impact of risk factor reduction on future AD 
prevalence in other regions. 
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INTRODUCTION   
Dementia has emerged as a major societal concern, endorsed by G8 nations because of the 
ageing populations of the world and the lack of any effective treatment for the disorder.7 
Assuming age specific prevalence rates remain stable, the number of dementia cases has been 
projected to more than triple worldwide by 2050, relative to current levels.8–10 One set of 
projections resulted in estimates of worldwide numbers of Alzheimer's Disease (AD, assumed 
as contributing to 60% of dementia cases overall11) at 106m by 2050, from 30m in 2010.  
Estimates for Europe foresee a doubling of dementia cases from 7·7m in 2001 to 15·9m in 
2040.9 Any development of effective treatments for the underlying pathological mechanisms 
of AD and other dementias should slow disease progression and is likely to also reduce 
disease related mortality rates, ultimately leading to increases in prevalence. The exact 
balance of reduced incidence of dementia at any given age and reduction in mortality will 
determine the degree to which dementia in the population might rise, or its rise be mitigated 
in future long lived populations.6,10,12  
Projection models indicate that primary prevention, targeted at reducing the incidence of AD, 
is likely to delay the onset and therefore reduce the future prevalence of AD and other 
dementias at particular ages.8 For example, one projection model estimates that delaying AD 
onset by one year would reduce the total worldwide number of cases of AD in the over 60's in 
2050 by 11%.10 However, another model suggests that even with delayed onset, due to 
population ageing, the total number of AD cases might still increase, with some attenuation, if 
people reach older ages in better health.12. Each of these scenarios have very different 
implications for society and it is important to use current knowledge to estimate what these 
might be.  
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To this end, focusing on primary prevention, Barnes & Yaffe1 reviewed the evidence from 
meta-analytic reviews of seven potentially modifiable risk factors for AD identified as having 
consistent evidence for an association by in a 2010 US National Institutes of Health 
independent state-of-the-science report: diabetes, midlife hypertension, midlife obesity, 
physical inactivity, depression, smoking, and educational attainment.13 From this, applied to 
the pattern of individual risk factors known in different populations, individual risk factor 
attributable risks were calculated giving an idea of single risk factor prevention potential. 
They then combined these single risk factor attributable risks to provide a total preventable 
fraction which has become widely quoted and was 51% and 54%, respectively for worldwide 
and US. Estimates for Europe were not provided separately and may be different due to 
different prevalence's of the risk factors in its population.  
A strength of the single risk factor approach is to highlight the potential for individual risk 
factors, assuming causality, but a major limitation of the estimate is that the estimated 
combined PAR makes the untenable assumption of independence of the risk factors – for 
example, three of the risk factors (diabetes, hypertension and obesity) constitute the metabolic 
syndrome and this syndrome is related to physical inactivity, all of which are related to 
educational level. Therefore, the combined PAR is likely to be a substantial overestimate. 
In this study, we build on this valuable approach to provide estimates of the PAR associated 
with diabetes, midlife hypertension, midlife obesity, physical inactivity, smoking, and 
educational attainment in the UK and Europe and show the potential impact of reducing these 
risk factors on the future prevalence of AD. We extend the method by adjusting the combined 
estimate of the PAR to account for the non-independence of the risk factors to provide more 
plausible estimates of the proportion of AD cases attributable to the risk factors.  
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METHODS 
Data 
The relative risk for AD for each of the seven risk factors (Table 1) was taken from the most 
recent and comprehensive meta-analysis on the associations of the seven modifiable risk 
factors with AD. Papers published between 1 January 2005 and 30 May 2014 were identified 
by searching PubMed. Older papers were taken from a previous systematic review.1 Using the 
search strategy implemented previously,1 articles written in English were identified using the 
terms “diabetes mellitus”, “hypertension”, “obesity”, “smoking”, “depression”, (“cognitive 
activity” or “education”), or (“physical inactivity” or “exercise”) in combination with 
(“Alzheimer” or “dementia”). For obesity, hypertension, educational attainment, smoking and 
physical inactivity no more recent and more comprehensive meta-analysis had been 
published since 2011. More comprehensive was defined as including a larger number of 
studies and pooled using an appropriate meta-analytic method. Therefore, the risk estimates 
used are the same as Barnes & Yaffe's previous paper.1 Different estimates were used for 
diabetes and depression. A meta-analysis of 19 studies prospective cohort studies provided a 
RR 1.46 (95% CI 1.20 to 1.77) for diabetes,14 which was only marginally higher than the 1.39 
used previously.[lu17] For depression, two recent meta analyses had provided estimates 
somewhat lower than the 1.90 used previously.[ownby20] One meta-analysis estimated a 
combined RR 1.66 (95% CI 1.29 to 2.24) based on of 4 prospective cohort studies15 whereas the 
other provided an estimate of 1.65 (95% CI 1.42 to 1.92) based on 23 studies.16 The latter 
estimate was used as it was based on a more comprehensive analysis. The prevalence of each 
of the seven risk factors in the UK and Europe were taken from various European population 
derived sources using the same age ranges as Barnes and Yaffe.1 Details of the definitions 
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used for each of the risk factors and the sources for the relative risks and prevalence rates 
used are provided in a webappendix. 
Statistical analysis 
Assuming there is a causal relation between a risk factor and a disease, the PAR is the 
proportion of cases of a disease in the population attributable to the risk factor. The PAR for 
each risk factor was calculated using Levin’s formula17 
     
            
                
 
where P is the population prevalence of the risk factor and RR is the relative risk. This formula 
is intended for unadjusted estimates but since the relative risks were obtained from multiple 
sources other methods were not available. The combined estimate of the PAR used by Barnes 
and Yaffe 1 assumed independence of risk factors 
                       
 The assumption of independence of risk factors is almost certainly biased, but was necessary 
due to a lack of other methods available. To account for non-independence of the risk factors a 
novel modification of the formula was used, which involved weighting the PAR for each risk 
factor 
                                  
where the weight w was computed using the estimate of 1 minus the proportion the variance 
shared (communality) with the other risk factors.  
The communality for each risk factor was estimated using data for adults aged 16 years and 
over from the 2006 Health Survey for England,18 where all seven risk factors were measured. 
The analysis was based on the presence of each risk factor ignoring the age ranges used to 
determine the relative risks.  The communality was calculated via principal components 
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analysis of the inter risk factor tetrachoric correlation matrix. Specifically, as the square of the 
loadings on the first two principal components since both had eigenvalues greater than one – 
the Kaiser criterion for selecting the number of components to extract.19 Together the two 
principal components explained 50% of the total variance between the risk factors, indicating 
considerable overlap. The communalities for each risk factor and self reported risk factor 
prevalence from Health Survey for England are given in Table 1.  
The total number of AD cases attributable to each risk factor was estimated by multiplying the 
PAR estimates by the present number of cases of AD in each region. The effect of reducing the 
relative prevalence of each risk factor by 10% or 20% per decade (e.g. ) on the future 
prevalence of AD was considered Previously published projections of the prevalence of AD 
for the four regions studied were used,10 which are openly available via the internet .20 This 
online projection tool is based on a multi-state model for the incidence and progression of 
AD21 that allows for local estimates of age-specific incidence and transition probabilities for 
progression from early to late stage disease. 
RESULTS 
Population attributable risks 
Estimates of the PAR of AD for each of the seven risk factors, along with the number of 
attributable cases in 2010 are given in Table 2. Owing to its high prevalence, around 1 in 5 
worldwide cases of AD were estimated to be to some extent attributable to low education. The 
figure was around 1 in 10 for the USA, Europe and the UK. In these regions physical inactivity 
was attributable to the largest proportion of cases.  Smoking and depression each accounted 
for around 1 in 10 cases of AD in all regions. Due to their relatively low prevalence, diabetes, 
hypertension and obesity were estimated to account for between 2 and 8% of cases of AD. 
Assuming independence, these seven risk factors combined were estimated to account for half 
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of the cases of AD worldwide (contributing to 16.7m out of 33.9m cases), in the USA (2.9m out 
of 5.3m) Europe (4·0m out of 7·2m), and  the UK (0·4m out of 0·8m). 
The risk factors have much in common and are not independent. Estimates of the degree of 
overlap range from 37% to 65% using the Health Survey for England (Table 1). Accounting for 
this non-independence of risk factors using the UK pattern of risk profiles provides a more 
conservative estimate of around one-third of cases, equating to 0·3m cases in the UK. 
Extrapolating the estimates for risk factor overlap to other regions indicates that around 9.6m 
cases worldwide, 1.6m cases in the USA, and 3.0m cases in Europe could be accounted for by 
potentially modifiable risk factors. This equates to approximately one-third of cases. 
Prevention 
The number of cases of AD worldwide is expected to increase from 30.8 million in 2010 to 
over 106.2 million in 2050. If the prevalence of the risk factors were reduced by 10% or 20% 
per decade over the next 40 years a significant proportion of AD in populations could be 
prevented (Table 3 & Figure 1). Worldwide, a 10% reduction per decade in each of the risk 
factors would result in a 8.3% (8.8 million) reduction in expected AD, and a 20% reduction per 
decade would lead to a reduction of 15.3% (16.2 million) in prevalence. Assuming a 10% 
reduction in the prevalence of risk factors per decade the future prevalence of AD in the USA, 
Europe and the UK, AD would be reduced by 0.8 million, 1.5 million, and 0.2 million, 
respectively. A 20% reduction would reduce the number of cases by 1.5 million, 2.8 million 
and 0.3 million, respectively.  
DISCUSSION 
The findings of this study indicate that, adjusting for non-independence of risk factors, 
around one third of worldwide can be related to the seven potentially modifiable risk factors 
10 
 
considered here. A figure that is relatively stable across regions.  This translates into around 
9.9 million of the estimated 30.1 million cases of AD worldwide in 2010. The worldwide 
prevalence of AD has been projected to more than treble between 2010 and 2050, increasing to 
106.2 million.10 Using this approach, reducing the prevalence of each of the risk factors by 10 
or 20% per decade would potentially reduce the worldwide prevalence of AD in 2050 by 
between 8% and 15% – between 8.8 and 16.2 million cases.  
Of the seven risk factors, largest proportion of cases of AD in USA, Europe and the UK could 
be attributed to physical inactivity. Current estimates suggest that around one third of the 
adult population in these regions is physically inactive.22 Other than AD, low physical activity 
is related to increased risk of other health outcomes estimated to be the fourth largest risk 
factor for non-communicable diseases.23  
The main strength of this study is that it extends previous estimates of the number of cases of 
AD attributable to potentially modifiable risk factors1 to adjust for the non-independence of 
the risk factors, a more conservative approach. The method used here provides considerably 
more realistic estimates. It should be noted that these still involve considerable uncertainty. 
The estimates of relative risk rely on secondary data, generally ascertained by meta-analysis. 
While we can be relatively confident of the robustness of the relative risk estimates we must 
note that they represent association and the causal nature of several risk factors can be 
questioned (particularly depression), with most supporting data being observational in 
nature. The true causal link between each risk factor and AD may be lower or accounted for 
by other factors. The risk relationships are taken at particular ages and clearly the inter-play 
between the risk factors operates throughout the life course and this analysis cannot model 
these factors, but highlight the urgent need to do so drawing on data across cohorts with 
representation of varying parts of the life course for different generations.  Ideally the model 
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would use dementia incidence and full modelling of changes with correct time course 
however sufficient data are not available.  
This analysis has used AD as the outcome of interest, given the earlier paper and the 
predominance of the use of the term AD in the literature. However, we note that most 
dementia in ageing populations is mixed in nature. Since over the age of 80 a 'pure'  
neuropathological finding in the brain is unlikely, it is more appropriate to consider the 
figures provided hear as indicating the burden of AD rather than AD 'cases'.24 For this reason, 
it is difficult to extrapolate the numbers further and define respective figures for the PAR for 
dementia in general, or even further to cognitive impairment. The models do not account for 
prevention reducing mortality rates from vascular causes and which could increase time spent 
living with AD or dementia, which may paradoxically increase the AD prevalence. For there 
to be an increase in time spent living with AD the mortality would need to decrease faster 
than the AD incidence rate.25 The more likely scenario, is an increased length of life for people 
without the risk factors, therefore surviving into an age at greater risk (but with reduced risk 
at that age), which would partially off-set the effect of reduced incidence on total AD 
prevalence.26 However, as people that do not develop AD would also experience an increased 
length of life the effect on the prevalence of AD is likely to be negligible. Nevertheless, our 
estimates for the number of cases prevented might still be considered optimistic.  
It is important to remember that the methods used to calculate the PAR here are necessarily 
crude, and therefore the PAR estimates provided are still imprecise but more realistic than the 
previous estimate.  Levin's PAR formula is intended for use with unadjusted relative risks, 
and estimates using adjusted relative risks are known to be biased.27 Unfortunately, due to the 
nature of the data it was not possible to use other methods, though we did attempt to account 
for the non-independence of the risk factors. The method used to adjust the combined PAR for 
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the non-independence of risk factors is novel and we are not aware of it being used elsewhere. 
While the integrity of this novel method has not been tested, we can be confident that it 
provides a more robust estimate that the unadjusted PAR. Limitations remain in that the 
natural history of these risk factors and their inter-relationships are more complex that a 
simple examination of co-occurent prevalent disorder. As noted above data needed to model 
the  potential for prevention fully are not currently available for different populations. Future 
modelling needs both better empirical data for the populations of interest and also 
development of methodologies that fully take the complexity of longitudinal data on multiple 
risk factors and complex outcomes, including missing data and study design features into 
account.  
In conclusion, we show that a considerable proportion of AD cases in Europe and the UK may 
be attributable to potentially modifiable risk factors . Although these estimates related to 
assumed AD they relate to the most common forms of dementia in the older populations, 
which is mixed in nature. There is large variation in the prevalence of each risk factor across 
countries. It is important for countries to consider the relative prevalence of each of the risk 
factors considered, and their inter-relationships at different ages across the life course in order 
to target those with the highest potential impact.  While the analysis here is necessarily 
simplistic and the role of other approaches in reducing disease burden for the tens of millions 
of people who will develop AD or other forms of will be important, public health 
interventions targeted at vascular risk factors and educational attainment are likely to achieve 
the greatest reduction in the prevalence of the modifiable risk factors considered with other 
major benefits to society and health care systems.  
Recent evidence from the few new generation population based studies in Europe using direct 
comparison suggest that there is a reduction in the age-specific prevalence of all dementias,28,29 
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particularly in the ninth decade in which the underlying neuropathology has been shown to 
include a substantial vascular component.24 Thus the reduction predicted through 
improvement of vascular health in populations may already be apparent. These findings 
should act as a spur to public health approaches across the lifecourse not just for prevention f 
premature mortality but for promoting healthier old age.  
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TABLE 1. RELATIVE RISKS AND SHARED VARIANCE BETWEEN RISK 
FACTORS 
 
Relative Risk1 95% Confidence Interval Communality2 
 Lower Upper  
Diabetes mellitus 1.46 1.20 1.77 50·9% 
Midlife hypertension  1.61 1.16 2.24 65·0% 
Midlife obesity  1.60 1.34 1.92 43·7% 
Depression 1.65 1.42 1.92 37·4% 
Physical inactivity 1.82 1.19 2.78 49·0% 
Smoking 1.59 1.15 2.2 58·1% 
Low education 1.59 1.35 1.86 45·6% 
 
Note. 1 Sources for the relative risk estimates are provided in webappendix 1. 2 The 
communality is the proportion of the variance in each risk factor shared with the other risk 
factors. This was estimated using the Health Survey for England 2006. 
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TABLE 2. ESTIMATES FOR POPULATION ATTRIBUTABLE RISK (PAR) AND 
THE NUMBER OF ATTRIBUTABLE CASES IN 2010 (N, IN THOUSANDS) 
 
Prevalence PAR 95% CI N 95% CI 
  Lower Upper  Lower Upper 
World        
   Diabetes mellitus  6.4% 2.9% 1.3% 4.7% 969 428 1,592 
   Midlife hypertension  8.9% 5.1% 1.4% 9.9% 1,746 476 3,369 
   Midlife obesity  3.4% 2.0% 1.1% 3.0% 678 387 1,028 
   Depression 13.2% 7.9% 5.3% 10.8% 2,679 1,781 3,671 
   Physical inactivity 17.7% 12.7% 3.3% 24.0% 4,297 1,103 8,122 
   Smoking 27.4% 13.9% 3.9% 24.7% 4,718 1,338 8,388 
   Low education 40.0% 19.1% 12.3% 25.6% 6,473 4,163 8,677 
   Combined1 
 
49.4% 25.7% 68.4% 16,754 8,703 23,188 
   Adjusted combined2 
 
28.2% 14.2% 41.5% 9,552 4,827 14,064 
USA        
   Diabetes mellitus  10.3% 4.5% 2.0% 7.3% 240 107 389 
   Midlife hypertension  14.3% 8.0% 2.2% 15.1% 425 119 798 
   Midlife obesity  13.1% 7.3% 4.3% 10.8% 386 226 570 
   Depression 19.2% 11.1% 7.5% 15.0% 588 395 796 
   Physical inactivity 32.5% 21.0% 5.8% 36.6% 1,115 308 1,942 
   Smoking 20.6% 10.8% 3.0% 19.8% 574 159 1,050 
   Low education 13.3% 7.3% 4.4% 10.3% 386 236 544 
   Combined1 
 
52.7% 25.9% 72.8% 2,796 1,374 3,858 
   Adjusted combined2 
 
30.6% 14.5% 45.3% 1,622 771 2,401 
Europe 
  
  
 
  
   Diabetes mellitus  6.9% 3.1% 1.4% 5.0% 222 98 364 
   Midlife hypertension  12.0% 6.8% 1.9% 13.0% 492 136 934 
   Midlife obesity  7.2% 4.1% 2.4% 6.2% 299 172 448 
   Depression 18.5% 10.7% 7.2% 14.5% 774 520 1,049 
   Physical inactivity 31.0% 20.3% 5.6% 35.6% 1,461 401 2,564 
   Smoking 26.6% 13.6% 3.8% 24.2% 978 277 1,745 
   Low education 26.6% 13.6% 8.5% 18.6% 978 614 1,342 
   Combined1 
 
54.0% 27.2% 73.7% 3,891 1,959 5,311 
   Adjusted combined2 
 
31.4% 15.3% 46.0% 3,033 1,472 4,332 
UK        
   Diabetes mellitus  4.1% 1.9% 0.8% 3.1% 14 6 23 
   Midlife hypertension  12.4% 7.0% 1.9% 13.3% 53 15 101 
   Midlife obesity  11.8% 6.6% 3.9% 9.8% 50 29 74 
   Depression 13.9% 8.3% 5.5% 11.3% 63 42 86 
   Physical inactivity 34.0% 21.8% 6.1% 37.7% 166 46 287 
   Smoking 20.0% 10.6% 2.9% 19.4% 80 22 147 
   Low education 23.6% 12.2% 7.6% 16.9% 93 58 128 
   Combined1 
 
52.0% 25.6% 71.9% 395 194 547 
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   Adjusted combined2 
 
30.0% 14.3% 44.4% 228 109 338 
 
Note. 1 Combined estimates of the population attributable risk and attributable cases, 
assuming independence of the risk factors. 2 Combined estimates of the population 
attributable risk and attributable cases, adjusting for non-independence of the risk factors.  
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TABLE 3. REDUCTION IN THE FUTURE PREVALENCE OF ALZHEIMER’S DISEASE WITH 10% OR 20% REDUCTION 
PER DECADE IN THE RELATIVE PREVALENCE OF THE EACH OF THE RISK FACTOR (N, IN THOUSANDS; % 
REDUCTION COMPARED TO BASE-CASE) 
 
2010 2020 2030 2040 2050 
 
N % N % N % N % N % 
World           
   Base-case 1 30,080 
 
41,230 
 
57,440 
 
80,570 
 
106,230 
    10% 30,080 0.0% 40,299 2.3% 54,915 4.4% 75,407 6.4% 97,418 8.3% 
   20% 30,080 0.0% 39,317 4.6% 52,430 8.7% 70,696 12.3% 90,009 15.3% 
USA                                                        
   Base-case 1 3,370 
 
4,160 
 
5,500 
 
7,390 
 
8,860 
    10% 3,370 0.0% 4,067 2.2% 5,251 4.5% 6,895 6.7% 8,085 8.7% 
   20% 3,370 0.0% 3,961 4.8% 4,994 9.2% 6,426 13.0% 7,412 16.3% 
Europe           
   Base-case 1 7,840 
 
9,550 
 
11,490 
 
14,080 
 
16,510 
    10% 7,840 0·0% 9,316 2·5% 10,940 4·8% 13,095 7·0% 15,011 9·1% 
   20% 7,840 0·0% 9,067 5·1% 10,392 9·6% 12,182 13·5% 13,727 16·9% 
UK           
   Base-case 1 760 
 
950 
 
1,250 
 
1,730 
 
1,940 
    10% 760 0·0% 927 2·4% 1,192 4·6% 1,613 6·8% 1,770 8·8% 
   20% 760 0·0% 904 4·9% 1,135 9·2% 1,506 13·0% 1,626 16·2% 
Note. 1 Base-case scenario estimated using the method described in Brookmeyer et al.10
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FIGURE 1. PROJECTED NUMBER OF AD CASES PREVENTED,  
CORRESPONDING TO 10 OR 20% REDUCTIONS PER DECADE IN EACH 
RISK FACTOR 
 
